Sulnox Group PLC — Director's Dealing 2020

May 19, 2020

National Storage Mechanism | Additional information

RNS Number : 2640N

SulNOx Group PLC

19 May 2020

SulNOx Group Plc (the "Company" or "SulNOx")

Admission to Trading of New Ordinary Shares

Change in Directors Shareholdings

(Aquis Stock Exchange: SNOX)

19 May 2020

Further to the announcement of 13 May 2020 of the completion of a placing of 575,000 ordinary 2p shares, the Company confirms that the application to the Aquis Stock Exchange Growth Market for admission of the new shares was successful. Dealings will commence at 8.00am today.

Directors Share Holdings

Following his participation in the placing, the holding by G V Lyon, Chairman has increased from 40,000 to 65,000 shares and this is included in the table below which displays the updated percentage holdings by the Board:

Director	Holding	Percentage of issued share capital
S J Bamford	9,125,000	10.68
N C P Nelson	270,000	0.31
M A Korsgaard	200,000	0.23
S J Retter	84,380	0.09
G V Lyon	65,000	0.07

Following this Admission, the Company's issued share capital is 85,364,093 ordinary 2p shares.

Enquiries:

SulNOx Group Plc: Nicholas Nelson, Chief Executive	[email protected]
Flagstaff, Strategic and Investor Communications Tim Thompson, Fergus Mellon	+44 (0) 207 129 1474
Aquis Stock Exchange Corporate Adviser: Alexander David Securities Limited	+44 (0) 20 7448 9820
David Scott - Corporate Finance,  James Dewhurst - Corporate Broking

The directors take responsibility for this announcement.

About SulNOx Group Plc

SulNOx, www.sulnoxgroup.com, has developed a hydrocarbon fuels conditioning and emulsifying process which enables more efficient fuel combustion, potentially leading to reduced fuel consumption and significantly lowered emissions.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [email protected] or visit www.rns.com.

END

NEXKKFBPABKDQPD